论文部分内容阅读
目的分析羟氯喹联合胸腺肽治疗干燥综合征的临床效果。方法选取我院2017年1月至2017年6月收治的10例干燥综合征患者作为此次实验研究对象,依照治疗方法的不同随机将10例患者分为两组进行讨论,对照组5例和观察组5例。对照组患者仅使用羟氯喹治疗,观察组患者使用羟氯喹联合胸腺肽治疗,比较两组患者治疗效果。结果两组患者经过治疗,红细胞沉降率、C反应蛋白原、类风湿因子、免疫球蛋白M、免疫球蛋白G、抗核抗体数值等各项指标均明显下降,但观察组患者下降变化明显大于对照组,两组数据比较差异有统计学意义(P<0.05)。结论使用羟氯喹联合胸腺肽治疗干燥综合征疗效显著,且治疗期间未出现严重毒副作用,安全可靠。
Objective To analyze the clinical effect of hydroxychloroquine combined with thymosin in the treatment of Sjogren’s syndrome. Methods Ten patients with Sjögren’s syndrome treated in our hospital from January 2017 to June 2017 were selected as the experimental subjects. Ten patients were randomly divided into two groups according to the different treatment methods. The control group (n = 5) and control group Observation group 5 cases. Patients in the control group were treated with hydroxychloroquine only, and those in the observation group were treated with hydroxychloroquine plus thymosin. The treatment effect was compared between the two groups. Results After treatment, the indexes of erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, immunoglobulin M, immunoglobulin G and antinuclear antibody were significantly decreased in both groups, but the changes in the observation group were significantly greater than those in the observation group In the control group, the difference between the two groups was statistically significant (P <0.05). Conclusions The use of hydroxychloroquine and thymosin in the treatment of Sjogren’s syndrome has obvious curative effect and no serious side effects during treatment, which is safe and reliable.